메뉴 건너뛰기




Volumn 46, Issue 9, 2008, Pages 921-922

Acute poisoning with moxonidine? A case report

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; DIAZEPAM; MANNITOL; MOXONIDINE;

EID: 55949108449     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650802307610     Document Type: Letter
Times cited : (4)

References (8)
  • 1
    • 55949098067 scopus 로고    scopus 로고
    • Summary of Product Characteristic - Physiotens 0.2 mg, Physiotens 0.3 mg, Physiotens 0.4 mg (Moxonidinum) (in Polish), The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Home Page, Poland. At http://www.urpl.gov.pl/ rejestr//Physiotens02_ 03_04.pdf. Accessed 19 June 2008.
    • Summary of Product Characteristic - Physiotens 0.2 mg, Physiotens 0.3 mg, Physiotens 0.4 mg (Moxonidinum) (in Polish), The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Home Page, Poland. At http://www.urpl.gov.pl/ rejestr//Physiotens02_ 03_04.pdf. Accessed 19 June 2008.
  • 2
    • 0029787839 scopus 로고    scopus 로고
    • Aspects of tolerability of centrally acting antihypertensive drugs
    • Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 27:49-54.
    • (1996) J Cardiovasc Pharmacol , vol.27 , pp. 49-54
    • Webster, J.1    Koch, H.F.2
  • 3
    • 0031723871 scopus 로고    scopus 로고
    • Imidazoline receptor mediated natriuresis: Central and/or peripheral effect?
    • Smyth DD, Penner SB. Imidazoline receptor mediated natriuresis: central and/or peripheral effect? J Auton Nerv Syst 1998; 72:155-162.
    • (1998) J Auton Nerv Syst , vol.72 , pp. 155-162
    • Smyth, D.D.1    Penner, S.B.2
  • 4
    • 0032242647 scopus 로고    scopus 로고
    • Moxonidine: Pharmacology, clinical pharmacology and clinical profile
    • Elliott HL. Moxonidine: pharmacology, clinical pharmacology and clinical profile. Blood Press 1998; 3:23-27.
    • (1998) Blood Press , vol.3 , pp. 23-27
    • Elliott, H.L.1
  • 5
    • 33645747198 scopus 로고    scopus 로고
    • Moxonidine: A review of its use in essential hypertension
    • Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs 2006; 66:477-496.
    • (2006) Drugs , vol.66 , pp. 477-496
    • Fenton, C.1    Keating, G.M.2    Lyseng-Williamson, K.A.3
  • 6
    • 0031668060 scopus 로고    scopus 로고
    • Safety and tolerabilility of moxonidine in the treatment of hypertension
    • Schachter M, Luszick J, Jäger B, Verboom C, Söhlke E. Safety and tolerabilility of moxonidine in the treatment of hypertension. Drug Saf 1998; 19:191-203.
    • (1998) Drug Saf , vol.19 , pp. 191-203
    • Schachter, M.1    Luszick, J.2    Jäger, B.3    Verboom, C.4    Söhlke, E.5
  • 7
    • 33646381125 scopus 로고    scopus 로고
    • Imidazoline receptors, novel agents and therapeutic potential
    • Head GA, Mayorov DN. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem 2006; 4:17-32.
    • (2006) Cardiovasc Hematol Agents Med Chem , vol.4 , pp. 17-32
    • Head, G.A.1    Mayorov, D.N.2
  • 8
    • 0027319607 scopus 로고
    • Comparative analysis of effects of imidazoline drugs on isolated rat heart atria
    • Radwańska A, Kaliszan R. Comparative analysis of effects of imidazoline drugs on isolated rat heart atria. J Physiol Pharmacol 1993; 44:73-87.
    • (1993) J Physiol Pharmacol , vol.44 , pp. 73-87
    • Radwańska, A.1    Kaliszan, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.